F18.25 Inhalant dependence with inhalant-induced psychotic disorder

Name of the Condition

• Common Name: Inhalant Dependence with Inhalant-Induced Psychotic Disorder
• Medical Term: Inhalant Dependence with Inhalant-Induced Psychotic Disorder

Summary

Inhalant dependence with inhalant-induced psychotic disorder is a substance use disorder characterized by a problematic pattern of inhalant use leading to clinically significant impairment or distress, accompanied by psychotic symptoms directly resulting from inhalant use. This condition involves a combination of physiological, behavioral, and cognitive symptoms related to continued use despite adverse consequences, including tolerance, withdrawal, and compulsive use, with the added complexity of psychotic features such as hallucinations or delusions.

Causes

Inhalant dependence with inhalant-induced psychotic disorder develops from repeated misuse of inhalants—substances that produce chemical vapors—for their psychoactive effects. Inhalants are often common household or industrial products, such as glue, paint thinners, aerosols, or solvents. Prolonged use can alter brain chemistry, leading to dependence and, in some cases, psychotic symptoms due to neurotoxic effects on the central nervous system.

Risk Factors

• Adolescents and young adults are more likely to experiment with inhalants.
• Individuals with a history of substance abuse or mental health disorders.
• Accessibility to inhalant products.
• Lack of proper supervision or guidance.

Symptoms

• Intense cravings or compulsive inhalant use.
• Coordination problems, dizziness, or lethargy.
• Unexplained behavioral changes such as aggression or mood swings.
• Cognitive impairment or memory issues.
• Withdrawal symptoms when use is reduced or stopped.
• Psychotic symptoms, including hallucinations, delusions, or disorganized thinking, directly linked to inhalant use.

Diagnosis

Diagnosis requires a comprehensive evaluation, including a detailed history of inhalant use and assessment of symptoms. Clinicians must confirm that psychotic symptoms are directly attributable to inhalant use rather than another condition. Physical exams, lab tests, and psychiatric assessments may be used to rule out other causes and determine the severity of dependence and psychotic features.

Treatment Options

Treatment typically involves a combination of medical management, behavioral therapy, and psychosocial support. Medical interventions may address withdrawal symptoms and psychotic features, while therapy focuses on reducing inhalant use and addressing underlying issues. Long-term care often includes counseling, support groups, and monitoring for relapse.

Prognosis and Follow-Up

Prognosis depends on the severity of dependence, the presence of psychotic symptoms, and adherence to treatment. With appropriate care, some individuals achieve sustained remission, though the risk of relapse remains. Regular follow-up is essential to monitor symptoms, adjust treatment, and address any co-occurring conditions.

Complications

• Worsening of psychotic symptoms or development of chronic psychosis.
• Severe withdrawal reactions.
• Organ damage from prolonged inhalant use.
• Increased risk of accidents or injuries due to impaired judgment.
• Social and occupational dysfunction.

Lifestyle & Prevention

• Avoiding inhalant use and educating others about its risks.
• Seeking healthy coping mechanisms for stress or peer pressure.
• Maintaining a supportive environment free of inhalant access.
• Engaging in regular physical and mental health check-ups.

When to Seek Professional Help

Seek help if experiencing intense cravings, withdrawal symptoms, or psychotic episodes related to inhalant use. Early intervention improves outcomes and reduces the risk of long-term complications.

Tips for Medical Coders

Document the presence of both inhalant dependence and inhalant-induced psychotic disorder to support the F18.25 code. Ensure clinical notes specify the direct link between inhalant use and psychotic symptoms, as this is critical for accurate coding. Include details on the duration and pattern of use, as well as any treatment interventions, to provide a comprehensive picture of the condition.